← brief for 2026-09-04 · Slowing decline

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

Canagliflozin is one of the SGLT2 drugs that slow kidney decline. Researchers went back to CREDENCE, a large randomized trial in people with type 2 diabetes and kidney disease, and sorted patients by how many other medicines they were already taking. The drug helped about the same, and was about as safe, in people on long medication lists as in people on short ones. That matters because doctors and patients often hold back from adding one more pill.

Who did this work

Yeung EK · Siriwardana A · Buizen L · Tang AHC · Jun M · Polkinghorne KR · Tang SCW · Kotwal S · Arnott C · Levin A · Jardine M · Lim SK

Source

Article · PubMed, the drug frontier · 2026 Sep 4
https://pubmed.ncbi.nlm.nih.gov/42695992/